FDA grants Teva approval for first EpiPen generic

The US Food and Drug Administration (FDA) yesterday granted Teva approval for the first generic version of EpiPen (epinephrine), an autoinjector pen used for the emergency treatment of allergic reactions.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Judge approves Pfizer’s $345m EpiPen settlement

18 November 2021 EpiPen buyers have secured final approval of a $345 million settlement with Pfizer in a consumer antitrust suit.

Europe

EpiPen patent revoked in Europe

2 May 2018 The European Patent Office has revoked a patent covering Mylan’s EpiPen injector after finding that patent amendments contravened the European Patent Convention (EPC).

Americas

Mylan finalises $465m settlement with US government

18 August 2017 Mylan has finalised a $465 million payment to the US government to settle a lawsuit about the classification of EpiPen Auto-Injector (epinephrine) under the Medicaid Drug Rebate Program.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

FDA grants Teva approval for first EpiPen generic

More on this story

Editor's picks

Editor's picks

More features